Article in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04676113 (Obesity in Pediatric Sickle Cell Disease), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04676113 completednot on this mapstarted 2021, after this paper: background citation
Obesity in Pediatric Sickle Cell Disease: A New Phenomenon
TypeobservationalSponsorUniversity of Mississippi Medical CenterRan2021 to 2022Enrolled100ConditionsSickle Cell Disease, Obesity, Childhood, Hypertension, Hyperlipidemia in Children
Jifang ZhouCenter for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0003-2590-8667
Jin HanCenter for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0003-0662-006X
Edith A NutescuCenter for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.
William L GalanterDepartment of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
Surrey M WaltonCenter for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.
Victor R GordeukDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, IL, USA.
Santosh L SarafDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0002-8584-4194
Gregory S CalipCenter for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0002-7744-3518
Funding
Institutional Career DevelopmentKL2TR002002 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PHILLIPS, SHANE A · 2016 to 2024
$6.8M
NCATS NIH HHS KL2 TR002002
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anemia, Sickle CellDiabetes Mellitus, Type 2DivingAdultBlack or African AmericanCohort StudiesHumansdiabetesepidemiologysickle cell disease
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al. · full record | OpenQuestion